Additional file 2 of Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression

Supplementary Material 2: Safety profile assessment of candidate drugs and prediction of binding affinity: (2a) Prediction of ADMET risk, pharmacokinetics, drug-likeness, and medicinal friendliness score of FDA-approved candidate drugs docked to protein signatures AKT1 and MDM2. (2b) binding affinity of AKT1 to candidate drugs and (2c) binding affinity of MDM2 to candidate drugs